Quest Diagnostics slides as Citi downgrade hits sentiment after recent rally
Quest Diagnostics shares fell after a fresh analyst downgrade to Neutral from Buy, pressuring sentiment following a strong run-up into early April. The call cited valuation and near-term risk/reward, even as the firm kept its price target unchanged at $185.
1. What’s moving the stock
Quest Diagnostics (DGX) is trading lower today as investors react to a new sell-side downgrade that shifted the narrative from momentum to valuation and near-term risk/reward. The downgrade to Neutral from Buy kept the price target at $185, signaling limited upside from recent levels and prompting profit-taking after the stock’s recent advance. (tipranks.com)
2. Why the downgrade matters now
The timing is notable with DGX set to report first-quarter 2026 results on April 21, 2026, a near-term catalyst that can amplify positioning changes and sensitivity to rating moves. With the stock having already digested optimistic FY2026 guidance earlier in the year, incremental negative research can weigh disproportionately on the shares. (newsroom.questdiagnostics.com)
3. Broader context investors are watching
Earlier this week, another firm trimmed its price target on DGX to $210 from $220 while maintaining an In Line rating, also framing the setup as more valuation-driven than fundamental deterioration. Together, these moves suggest Wall Street is increasingly focused on how much of the 2026 growth outlook is reflected in the current stock price heading into earnings. (investing.com)